Case Study

Disseminated Cutaneous Histoplasmosis in a 30-Year-Old Male HIV-Positive Patient: A Rare Case Report

Vikas Kumar¹, Astha²*, Yatendra Chahar¹ and Arti Agrawal¹

¹Sarojini Naidu Medical College, Agra, India  
²F. H. Medical College, Agra, India

*Corresponding author

A B S T R A C T

Histoplasmosis is a systemic mycotic infection caused by *Histoplasma capsulatum*, a dimorphic fungus. Although histoplasmosis can occur in immunocompetent persons, but immunocompromised individuals, such as people with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), are at high risk of developing disseminated disease. In AIDS patients, mortality may approach 50%, due to disseminated histoplasmosis, especially in those with severe manifestations. We present a case of disseminated histoplasmosis in a 30-year-old, HIV-positive male patient on antiretroviral treatment, who presented to the Skin outpatient clinic with multiple papulonodular lesions on the face, neck, trunk and ulcers in oral cavity. General complaints included fever, malaise and weight loss, along with hepatosplenomegaly on examination. Investigations revealed pancytopenia, altered liver function and renal dysfunction. CD4 cell count was 72 cells/µl. The patient was started on Amphotericin B for 2 weeks as induction therapy followed by oral itraconazole as maintenance therapy. Histoplasmosis is rarely reported from India, which may be on account of its varied clinical presentation and lack of awareness among dermatologists, hence disseminated histoplasmosis should be considered as a differential diagnosis in an immunocompromised patient presenting with cutaneous lesions, as it is necessary for the early diagnosis and proper management of the patient.

Keywords

Histoplasma capsulatum, Disseminated histoplasmosis, HIV, AIDS

Accepted: 07 May 2019
Available Online: 10 June 2019

Introduction

Histoplasmosis is a systemic mycotic infection caused by *Histoplasma capsulatum*, a dimorphic fungus (1). An American physician, Samuel Darling, who was working in the Canal Zone in Panama, first described histoplasmosis a little over a century ago. He described disseminated form of the disease in a fatal case from Martinique (2). Histoplasmosis occurs in specific endemic areas, such as, North, Central and South America, Africa, India and Southeast Asia while sporadic cases have also been reported in Europe. *H. capsulatum* is found in the soil of the endemic areas, especially those contaminated with bird and bat droppings (3). The clinical presentation of histoplasmosis ranges from asymptomatic infection or mild respiratory illness to severe disseminated disease. Although histoplasmosis can occur in immunocompetent persons, but
immunocompromised individuals, such as people with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), are at high risk of developing disseminated disease. In AIDS patients, mortality may approach 50%, due to disseminated histoplasmosis, especially in those with severe manifestations (4). Although only occasionally reported in the pre-HIV-infection era, it became a public health issue after the AIDS pandemic, and was listed among the AIDS-defining illnesses by Center for Diseases Control and Prevention (CDC) in 1987 (5). Infection occurs when infectious microconidia of Histoplasma capsulatum get aerosolized and are inhaled into the lower airways. In the alveolar space conidia get recognized and phagocytised by the resident macrophages. Inside the macrophages, conidia convert to yeast form—a necessary step in the pathogenesis of histoplasmosis. If cellular immunity is defective, the fungus proliferates and disseminates throughout the body, causing tissue destruction and multi-organ failure, thus leading to progressive dissemination which can be fatal if left untreated (6).

We present a case of disseminated cutaneous histoplasmosis in a 30-year-old, HIV-positive male patient on antiretroviral treatment, who presented to the Skin outpatient clinic with multiple papulonodular lesions on the face, neck, trunk and ulcers in oral cavity.

Case report

In March, 2019, a 30-year-old male, known case of AIDS (Acquired immunodeficiency syndrome) on antiretroviral treatment, presented to the Skin outpatient clinic of Sarojini Naidu Medical College, Agra with multiple skin colored papulonodular lesions on the face, neck, trunk and ulcers in oral cavity. General complaints included fever, malaise and weight loss, along with hepatosplenomegaly on examination. Investigations revealed pancytopenia, altered liver function and renal dysfunction. CD4 cell count was 72 cells/µl. The patient was then referred to the Microbiology Department for fungal culture of the cutaneous lesions. Culture was performed from skin scrapings collected from the cutaneous lesions, in Sabouraud Dextrose Agar (SDA) tube and incubated at 25°C. On macroscopic examination, white, cottony colonies were observed after 3 weeks and on microscopic examination of the Lactophenol cotton blue (LPCB) mount, presence of septate hyphae, with tuberculate macroconidia and smooth-walled microconidia were noted, suggestive of histoplasmosis. The conversion from the mold phase to the yeast phase is necessary for accurate diagnosis of H. capsulatum. The conversion (dimorphism) test was done by inoculating a portion of the mold colony of suspected Histoplasma on Brain Heart Infusion (BHI) blood agar, and incubating at 37°C for the appearance of yeast form of the isolate. On macroscopic examination, the growth of smooth, white yeast-like colonies, was seen on BHI blood agar, incubated at 37°C. On microscopic examination, budding yeast cells were seen in the Gram stained smear and LPCB mount, thus confirming the diagnosis of histoplasmosis. Fungi belonging to the genus Sepedonium also form similar tuberculate macroconidia but they are not dimorphic and do not form microconidia. Pancytopenia with CD4 count of 72 cells/µl and altered liver and renal functions, in the setting of AIDS was concerning for disseminated histoplasmosis, and thus blood culture was also done. Blood culture showed H.capsulatum growth, consistent with the suspected diagnosis of disseminated Histoplasma capsulatum infection.

The patient was started on Amphotericin B for 2 weeks as induction therapy, then
switched over to oral itraconazole as maintenance therapy. The anti-retroviral therapy was also continued with the advice for regular follow-up.

**Results and Discussion**

Histoplasmosis is rarely reported from India, which may be on account of its varied clinical presentation and lack of awareness among dermatologists. Histoplasmosis from India, was first reported by Panja and Sen, in 1959 (7). *H. capsulatum* is believed to be endemic in some East Indian states like West Bengal, where a prevalence of skin positivity of 9.4% to histoplasmin antigen, was shown by a study (8). A few sporadic cases have been reported from South India as well (9). Histoplasmosis mortality is greater than 33% in immunosuppressed patients, while in immunocompetent individuals it is approximately 17% (10) (Fig. 1–3).

**Fig.1** Multiple papulonodular lesions on face and neck

**Fig.2** White, cottony colonies on SDA
The disseminated disease is the most commonly reported form in immunocompromised individuals and skin lesions are usually the manifestations of disseminated histoplasmosis. Primary cutaneous histoplasmosis is very rare, with cutaneous lesions as the initial presentation of histoplasmosis in about 10% cases, serving as the marker for AIDS in areas endemic for histoplasmosis (11). In the present case, though there were no signs of pulmonary involvement, the presence of pancytopenia, altered liver function and renal dysfunction, CD4 cell count of 72 cells/µl, hepatosplenomegaly, with multiple papulonodular lesions on the face, neck and ulcers in oral cavity indicate secondary cutaneous histoplasmosis.

Hence, disseminated histoplasmosis should be considered as a differential diagnosis in an immunocompromised patient presenting with cutaneous lesions. After the diagnosis is confirmed, effective and proper antifungal treatment should be timely delivered to the patient, aiming to enhance the clinical recovery.

References


How to cite this article: